Canopy Growth Corp vs Nuwellis Inc — how do they compare? Canopy Growth Corp trades at $1 (market cap $421.10M), while Nuwellis Inc trades at $1.49 (market cap $542.80K). The key difference: Canopy Growth Corp is far larger — about 775.8× Nuwellis Inc's market cap, and Canopy Growth Corp is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| CGC | NUWE | |
|---|---|---|
Market Cap | $421.10M | $542.80K |
Sector | Health | Technology |
52-Week High | $1.92 | $220.50 |
52-Week Low | $0.86 | $1.42 |
Enterprise Value | $378.55M | -$1.27M |
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.95, down 1.86% in the last session, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year, beating estimates, but continues to post net losses. Recent news highlights expansion in European cannabis markets and cost-cutting efforts, while the stock remains volatile amid regulatory uncertainty.
Outlook is cautious due to persistent losses and high debt, though improving cash flow and revenue growth offer potential upside. Key risks include regulatory delays in U.S. cannabis rescheduling and competitive pressures. Investors should weigh the speculative nature against any positive regulatory catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →